ripretinib (Qinlock)

From Aaushi
Jump to navigation Jump to search

Indications

Contraindications

Dosage

Tablets: 50 mg

Pharmacokinetics

Adverse effects

Mechanism of action

More general terms

References

  1. Aakash B Deciphera's Cancer Drug Improves PFS in GI Stromal Tumors. Medscape Aug 13, 2019 https://www.medscape.com/viewarticle/916779
  2. Dhillon S. Ripretinib: First Approval. Drugs. 2020 Jul;80(11):1133-1138. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32578014 PMCID: PMC7595980 Free PMC article. Review.
  3. Fung S, Shirley M. Ripretinib: A Review in Gastrointestinal Stromal Tumours as Fourth-or Later-Line of Therapy. Drugs. 2022 Oct;82(15):1541-1548. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36282417 Review.
  4. Blay JY, Serrano C, Heinrich MC et al Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 Jul;21(7):923-934. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32511981 PMCID: PMC8383051 Free PMC article. Clinical Trial.

Database